Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: Effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 2, 2004, Pages 351-355

  Fraley, Mark E ^a   Arrington, Kenneth L ^a   Buser, Carolyn A ^a   Ciecko, Patrice A ^a   Coll, Kathleen E ^a   Fernandes, Christine ^a   Hartman, George D ^a   Hoffman, William F ^a   Lynch, Joseph J ^a   McFall, Rosemary C ^a   Rickert, Keith ^a   Singh, Romi ^a   Smith, Sheri ^a   Thomas, Kenneth A ^a   Wong, Bradley K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL HERG; QUINOLINE DERIVATIVE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DOG; DOSE RESPONSE; FIBROSARCOMA; HUMAN; HUMAN CELL; MONKEY; MOUSE; NONHUMAN; PLASMA CLEARANCE; RAT; SARCOMA CELL;

EID: 0346729888     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.11.007     Document Type: Article

References (30)

1. Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D'Amore P.A., Folkman J. Biochem. Biophys. Res. Commun. 193:1993;631.
2. Giatromanolaki A., Sivridis E., Athanassou N., Zois E., Thorpe P.E., Brekken R.A., Gatter K.C., Harris A.L., Koukourakis I.M., Koukourakis M.I. J. Path. 194:2001;101.
3. Enomoto H., Inoki I., Komiya K., Shiomi T., Ikeda E., Obata K., Matsumoto H., Toyama Y., Okada Y. Am. J. Pathol. 162:2003;171.
4. Detmar M. Dermatol. Sci. 24:2000;S78.
5. For reviews, see: (a) Carmeliet P., Jain R.K. Nat. 407:2000;249 (b) Folkman J. Nat. Med. 1:1995;27.
6. For reviews, see: (a) Carmeliet P., Jain R.K. Nat. 407:2000;249 (b) Folkman J. Nat. Med. 1:1995;27.
7. Zetter B.R. Annu. Rev. Med. 49:1998;407.
8. (a) Hanahan D., Folkman J. Cell. 86:1996;353
9. (b) Holmgen L., O'Reilly M.S., Folkman J. Nat. Med. 1:1995;149.
10. (a) Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Cancer Res. 60:2000;203
11. (b) Thomas K.A. J. Biol. Chem. 271:1996;603.
12. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Nature. 362:1993;841.
13. Witte L., Hicklin D., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Cancer Metastasis Rev. 17:1998;155.
14. (a) Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J. Ö., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. Clin. Cancer Res. 2003;327
15. (b) Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., Boffey S.J., Valentine P.J., Curwen J.O., Musgrove H.L., Graham G.A., Hughes G.D., Thomas A.P., Stokes E.S.E., Curry B., Richmond G.H.P., Wadsworth P.F., Bigley A.L., Hennequin L.F. Cancer Res. 62:2002;4645
16. (c) Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Müller M., Wood J., Martiny-Baron G., Unger C., Marmé D. Cancer Res. 60:2000;4819.
17. Hurwitz H., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W., Berlin J., Griffing S., Novotny W., Holmgren E., Kabbinavar F. Proc. Am. Soc. Clin. Oncol. 22:2003;. Abstract 3646.
18. For recent reviews, see: (a) Connell R.D. Expert Opin. Ther. Pat. 12:2002;1763 (b) Boyer S.J. Curr. Top. Med. Chem. 2:2002;973.
19. For recent reviews, see: (a) Connell R.D. Expert Opin. Ther. Pat. 12:2002;1763 (b) Boyer S.J. Curr. Top. Med. Chem. 2:2002;973.
20. (a) Fraley, M. E.; Antanavage, J.; Arrington, K. L.; Ciecko, P. A.; Coll, K. E.; Gibbs, J. B.; Hambaugh, S. R.; Hartman, G. D.; Heimbrook, D. C.; Hoffman, W. F.; Hungate, R. W.; Kohl, N. E.; Mao, X.; McFall, R. C.; Rands, E.; Rickert, K.; Sepp-Lorenzino, L.; Shipman, J. M.; Tebben, A. J.; Thomas, K. A. Presented at the 224th National Meeting of the American Chemical Society, Boston, MA, August 2002; Abstract MEDI-221.
21. (b) Fraley, M. E.; Hoffman, W. F.; Arrington, K. L.; Hungate, R. W.; Hartman, G. D.; McFall, R. C.; Coll, K. E.; Rickert, K.; Thomas, K. A.; McGaughey, G. B. Curr. Med. Chem., in press.
22. 50 value.
23. 50 value represents the inhibition of VEGF-stimulated mitogenesis as determined in human umbilical vein endothelial cells. Refer to U.S. Patent 6,306,874 for assay details. Values are reported as the average of at least two determinations.
24. (a) Sepp-Lorenzino, L.; Mao, X.; Rands, E.; Connolly, B.; Antanavage, J. ; Shipman, J.; Hoffman, W.; Fraley, M.; Ciecko, P.; Gibbs, J.; Hartman, G.; Heimbrook, D.; Kohl, N.; Thomas, K. Proc. Am. Assoc. Cancer Res. 2002, 43; Abstract 5346.
25. (b) Sepp-Lorenzino, L.; Rands, E.; Mao, X.; Connolly, B.; Shipman, J.; Antanavage, J.; Hill, S.; Davis, L.; Beck, S.; Rickert, K.; Coll, K.; Ciecko, P.; Fraley, M.; Hoffman, W.; Hartman, G.; Heimbrook, D.; Gibbs, J.; Kohl, K.; Thomas, K. Cancer Res., in press.
26. The hERG IP values were determined through binding competition experiments using membrane preparations from human embryonic kidney cells that constitutively express hERG. For an overview of currently available drug cardiotoxicity assays, see Netzer R., Ebneth A., Bischoff U., Pongs O. Drug Discov. Today. 6:2001;78.
27. For a recent review, see: De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Drug Safety. 25:2002;263.
28. Partition coefficients were determined by HPLC analysis using the octanol/aqueous shake flask method.
29. Borror A.L., Chinoporos E., Filosa M.P., Herchen S.R., Petersen C.P., Stern C.A., Onan K.D. J. Org. Chem. 53:1988;2047.
30. Marsais F., Godard A., Queguiner G. J. Heterocycl. Chem. 26:1989;1589.